Skip to main content
The Maple Markets

Canadian Securities Exchange (CSE) · BIOV.CN · ISIN CA09076M2004

BioVaxys Technology Corp.

No trading activity has been reported for this listing since May 5, 2026. It may be delisted, halted or inactive.

0.0700 CAD

May 5, 2026

Sign in to add to portfolio

BioVaxys Technology Corp. (BIOV.CN) trades on the Canadian Securities Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 2.04M CAD. The company reports around 3 employees. Its ISIN is CA09076M2004. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Canadian Securities Exchange (CSE)

ISIN

CA09076M2004

Sector

Healthcare

Industry

Biotechnology

Country

CA

Market cap

2.04M CAD

Employees

3

Previous close

0.06 CAD

Day range

0.07 – 0.07

52-week range

0.03 – 0.40

Volume

13.47K

50-day average

0.08 CAD

200-day average

0.20 CAD

Asset type

Equity

About BioVaxys Technology Corp.

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

Company website

Frequently asked

+
What is the BIOV.CN share price today?
This page shows the latest available BioVaxys Technology Corp. (BIOV.CN) price with its change against the prior close. Values are delayed or previous-close, not real-time.
+
Where is BioVaxys Technology Corp. listed?
BioVaxys Technology Corp. trades on the Canadian Securities Exchange under the symbol BIOV.CN, ISIN CA09076M2004.
+
How large is BioVaxys Technology Corp.?
Its market capitalisation is approximately 2.04M CAD, based on the latest available price and share count from our data provider.

All BioVaxys Technology Corp. data comes from exchange and provider feeds for the Canadian Securities Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.

We use necessary cookies to run the site and, only with your permission, analytics cookies to understand what readers use. Cookie policy